Long-Term Mortality after Recombinant Growth Hormone Treatment for Isolated Childhood Short Stature: Report of the French SAGhE Study

Authors:

Abstract
Recombinant growth hormone treatment is widely used to promote growth in children with short stature. Little is known about the long-term safety of such treatment. SAGhE (safety and appropriateness of growth hormone treatments in Europe) is a large study evaluating the long-term health of individuals treated with recombinant growth hormone in childhood in eight European countries. We report on the mortality results of the study performed in France where it was initiated before the rest of Europe. This population-based cohort study was based on the French population-based register of children treated with growth hormone. 6928 short children diagnosed with idiopathic isolated growth hormone deficiency, idiopathic short stature or born short for gestational age who started recombinant growth hormone treatment between 1985 and 1996. Follow-up data on vital status were available in September 2009 for 94.7% of the patients, providing 116,403 person-years of observation. We measured all-cause and cause-specific mortality and calculated standardised mortality ratios (SMR) and hazard ratios (HR, using the category with the lowest exposure level as the reference). All-cause mortality was higher in treated children than in the general population (SMR 1.33. 95% CI 1.08–1.64). In multivariate analysis adjusted for height at the start of treatment, the use of high doses typically exceeding 50 µg/kg/day was consistently associated with mortality rates almost three times those for the low-dose regimen, using both external and internal references (adjusted SMR 2.94, 95% CI 1.22–7.07, adjusted HR 2.79, 95% CI 1.14–6.82). Cancer-related mortality was not higher than for the general population, although bone tumour-related mortality was five times higher (SMR 5.00, 95% CI 1.01–14.63). An increase in mortality due to diseases of the circulatory system (SMR 3.07, 95% CI 1.40–5.83), and subarachnoid or intracerebral haemorrhage in particular (SMR 6.66, 95% CI 1.79–17.05), was also observed. In conclusion, mortality rates were significantly increased in this population of otherwise healthy but short children treated with recombinant growth hormone, particularly in those who had received the highest doses. Specific effects were detected in terms of death due to bone tumours or cerebral haemorrhage, but not for all cancers. These results highlight the need for additional studies of long-term mortality and morbidity after growth hormone treatment in childhood. Sources of Research Support: The study was funded by Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS, the French drug safety agency), Direction Generale de la Sante (DGS, French Ministry of Health), Institut National du Cancer (INCa) and a Commission of European Communities grant (HEALTH-F2-2009-223497). J-CC: Investigator, Lilly USA, LLC; Scientific Board Member, Pfizer Global R&D. Nothing to Disclose: EE, FL, DM-H, FK, GR, JC